Recently, “IA001 Injection” received clinical trial approval issued by National Medical Products Administration, which was cooperatively developed by Shanghai Destiny Biotech Co., Ltd., a subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd., and Liaoning Grand Nuokang Bio-Pharmaceutical Co., Ltd., a subsidiary of China Grand Enterprises.